利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

90 条记录 (耗时 0.043 秒)

    BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE
    32.
    发明授权
    BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 有权
    生物标志物在选择心力衰竭治疗中的作用

    公开(公告)号：EP2929354B1

    公开(公告)日：2018-04-18

    申请号：EP13799310.1

    申请日：2013-12-04

    申请人： Roche Diagnostics GmbH ,  F. Hoffmann-La Roche AG

    发明人： ZAUGG, Christian ,  BLOCK, Dirk ,  WIENHUES-THELEN, Ursula-Henrike ,  BRUNNER, Hans-Peter ,  KRAUSE, Friedemann ,  MODEL, Fabian ,  ROLNY, Vincent

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8139 ,  G01N2800/325 ,  G01N2800/52 ,  G01N2800/60

    摘要： The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
    36.
    发明公开
    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
    方法和组合物诊断和预后判断肾功能衰竭和肾损害

    公开(公告)号：EP3077819A1

    公开(公告)日：2016-10-12

    申请号：EP14868424.4

    申请日：2014-12-03

    申请人： Astute Medical, Inc. ,  University of Pittsburgh - Of the Commonwealth System of Higher Education

    发明人： MCPHERSON, Paul ,  KELLUM, John, A.

    IPC分类号： G01N33/566

    CPC分类号： A61K38/13 ,  A61K31/357 ,  A61K31/366 ,  A61K31/436 ,  A61K31/437 ,  A61K31/453 ,  A61K31/55 ,  A61K31/585 ,  A61K38/1754 ,  A61K38/55 ,  A61K45/06 ,  G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/50

    摘要： It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G
    0 /G
    1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G
    0 /G
    1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

    摘要翻译： 它是本发明的一个目的是通过治疗受试者与化合物做调节细胞周期以提供用于从急性肾损伤的受试者的保护方法和组合物。 调节细胞周期可以包括诱导G0 / G1期细胞周期停滞和/或诱导细胞周期进程。 如以下实例阐述，其诱导G0 / G1细胞周期阻滞可以保护受试者从AKI，并且可以提前的预防性使用，或作为治疗以下的化合物的甚至单次给药，各种处理或条件也已知是有害 肾脏，通过逮捕任选发行紧随其后。 一旦AKI被建立，细胞周期进程可以被诱导以增加替换丢失和损坏细胞的

    RADIATION EXPOSURE DIAGNOSTIC MARKER IGFBP-5, COMPOSITION FOR RADIATION EXPOSURE DIAGNOSIS BY MEASURING THE EXPRESSION LEVEL OF THE MARKER, RADIATION EXPOSURE DIAGNOSTIC KIT COMPRISING THE COMPOSITION, AND METHOD FOR DIAGNOSING RADIATION EXPOSURE USING THE MARKER
    40.
    发明公开
    RADIATION EXPOSURE DIAGNOSTIC MARKER IGFBP-5, COMPOSITION FOR RADIATION EXPOSURE DIAGNOSIS BY MEASURING THE EXPRESSION LEVEL OF THE MARKER, RADIATION EXPOSURE DIAGNOSTIC KIT COMPRISING THE COMPOSITION, AND METHOD FOR DIAGNOSING RADIATION EXPOSURE USING THE MARKER 有权
    曝光诊断标记物IGFBP-5 AND METHOD FOR诊断辐射暴露的BY测量标记的表达水平的

    公开(公告)号：EP2799546A1

    公开(公告)日：2014-11-05

    申请号：EP12862230.5

    申请日：2012-05-09

    申请人： Korea Institute of Radiological & Medical Sciences

    发明人： KIM, Kwang Seok ,  BAE, Sang Woo ,  CHOI, Kyu Jin ,  KIM, Eun Sook

    IPC分类号： C12N15/11 ,  G01N33/53 ,  G01N33/68 ,  C12Q1/68

    CPC分类号： C12Q1/6881 ,  C07K2/00 ,  C07K14/4743 ,  C12N15/113 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/4745 ,  G01N2333/71 ,  G01N2800/40

    摘要： The present invention provides: a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein; a kit for radiation exposure diagnosis including the composition; a method of diagnosing radiation exposure by measuring the expression level of the IGFBP-5 gene at an mRNA or the protein in a patient's sample; a method of screening an agent for enhancing radiation sensitivity by selecting a sample having increased expression levels of the IGFBP-5 gene at an mRNA or the protein compared to those of a control group; a method of screening an agent for radiation protection by selecting a sample having decreased expression levels of the IGFBP-5 gene at an mRNA or the protein compared to those of a control group; a composition for enhancing radiation sensitivity including an agonist to expression or action of the IGFBP-5 gene at an mRNA or the protein; and a composition for radiation protection including an antagonist to expression or action of the IGFBP-5 gene at an mRNA or the protein.

    摘要翻译： 本发明提供：用于治疗辐射暴露诊断包括对胰岛素样生长的表达水平的测量的试剂的组合物因子结合蛋白5（IGFBP-5）基因在mRNA或蛋白质; 用于治疗辐射暴露诊断包含所述组合物的试剂盒; 通过测量mRNA或向患者的样品中的蛋白的IGFBP-5基因的表达水平诊断辐射曝光的方法; 筛选基因的方法用于通过选择在与mRNA或相比，这些对照组中的蛋白质具有IGFBP-5的增加的表达水平的样品增强辐射敏感性的试剂; 通过选择在与mRNA或相比，这些对照组中的蛋白质具有IGFBP-5的减少的表达水平的样品筛选基因辐射防护的试剂的方法; 一种用于增强辐射敏感性的包含激动剂在mRNA或蛋白质表达或IGFBP-5基因的作用的组合物; 和辐射防护的组合物包含拮抗剂表达或IGFBP-5基因的作用在mRNA或蛋白质的。